Axsome Therapeutics Inc

Director, In-House Global Health Economics & Outcomes Research (HEOR) - (East Coast Candidates)

United States

Not SpecifiedCompensation
Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
BiopharmaceuticalIndustries

Requirements

Candidates must possess an advanced degree (PhD, PharmD, MS) in health economics, public health, or a related scientific discipline, coupled with a minimum of 7 years of cumulative experience in health economics and outcomes research within the pharmaceutical, biotechnology, or a related environment. A strong publication record in peer-reviewed journals and expertise in formulating and leading innovative HEOR research projects are essential. The role also requires strong verbal and written communication skills, including the ability to present complex concepts persuasively to diverse audiences. Candidates must be based on the East Coast.

Responsibilities

The Director of Global HEOR will lead the execution of complex HEOR evidence generation strategies, including cost-effectiveness analysis, budget impact models, observational studies, ITCs, meta-analyses, systematic reviews, and patient-reported outcomes development. They will collaborate with internal HEOR and Market Access teams to implement scientific engagement strategies with external customers like Payers and PBMs. The role involves serving as a resource for delivering clinical and healthcare economic information to formulary decision-makers, proactively communicating product information, and responding to unsolicited customer requests. Additionally, the Director will capture and communicate customer insights, contribute to the design of observational research studies, collaborate with medical communications on publication strategies, and partner with various internal departments to develop and implement HEOR strategies supporting product value.

Skills

Health Economics
Outcomes Research
HEOR
Cost-effectiveness analysis
Budget impact models
Observational studies
Meta-analyses
Systematic reviews
Patient-reported outcomes
Market Access
Scientific engagement
Formulary decision-making
Regulatory compliance
Standard Operating Procedures (SOPs)

Axsome Therapeutics Inc

Develops therapies for CNS disorders

About Axsome Therapeutics Inc

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

New York City, New YorkHeadquarters
2012Year Founded
$430.7MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees

Benefits

Performance Bonus
Company Equity

Risks

Increased competition from companies like Compass Pathways in the CNS market.
Potential delays in AXS-07 launch amid growing market anticipation.
Departure of key personnel like Lori Englebert may impact strategic direction.

Differentiation

Axsome focuses on CNS disorders with limited current treatment options.
AXS-05, an NMDA receptor antagonist, targets major depressive disorder and treatment-resistant depression.
Axsome's balanced portfolio includes both clinical and research stage products.

Upsides

FDA's fast-tracking of CNS treatments could expedite Axsome's drug approvals.
Increased investment in CNS R&D drives innovation, benefiting Axsome's pipeline.
Growing personalized medicine trend offers Axsome opportunities for tailored therapies.

Land your dream remote job 3x faster with AI